)
Harvard Bioscience (HBIO) investor relations material
Harvard Bioscience Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue rose 7.8% YoY to $22.2M, marking a second consecutive quarter of growth; CRO, China and distribution demand supported sales.
Adjusted EBITDA was $1.8M; lower-margin product and channel mix pressured margins and led to a cut in FY26 adjusted EBITDA growth guidance.
Nine-month revenue increased 4.6% to $65.7M; net loss was $9.0M, with prior-year results affected by a $48.0M goodwill impairment.
Financial highlights
Q3 GAAP gross margin was 55.4% vs. 58.4%; adjusted gross margin was 57.1% vs. 59.2%.
Operating loss was $1.2M vs. $0.2M operating income; adjusted operating income was $1.2M vs. $1.5M.
Adjusted EBITDA was $1.8M vs. $2.0M; adjusted EBITDA margin was 7.9% vs. 9.6%.
Net loss was $2.6M vs. $1.2M; GAAP diluted loss per share was $0.58 vs. $0.28, and adjusted diluted loss per share was $0.06 vs. $0.04.
Nine-month operating loss was $3.3M vs. $50.3M; nine-month net loss was $9.0M vs. $53.9M.
Outlook and guidance
FY26 revenue growth guidance remains 3%–5% and adjusted gross margin guidance 57%–59%; adjusted EBITDA growth guidance was cut to -1%–4% from 6%–10%.
Q4 revenue guidance is $23.7M–$25.5M, adjusted gross margin 59%–61%, and adjusted EBITDA $3.8M–$4.2M.
Q4 outlook anticipates YoY revenue growth across CMT and NPI platforms, sequential adjusted gross-margin expansion and improving YoY adjusted EBITDA profitability.
Management expects gross margin in the 60% range in 2027; ~75% of Project Viking benefits relate to gross margin.
Project Viking is expected to save $3M in 2027 and $4M annually from 2028.
- Q2 2026 revenue up 11% year-over-year, guidance raised, and CMT/China drove growth.HBIO
Q2 2026 - All board-recommended proposals, including director elections and plan amendments, were approved.HBIO
AGM 2026 - Operational consolidation, innovation, and recurring revenue drive margin and growth targets.HBIO
Sidoti Micro-Cap Virtual Conference - Strategic focus, operational streamlining, and innovation drive growth and recurring revenue.HBIO
Investor presentation - Q1 2026 gross margin rose to 59% as revenue fell, with net loss narrowing and outlook reaffirmed.HBIO
Q1 2026 - Both proposals, including a reverse stock split, passed with over 97% approval.HBIO
EGM 2026 - Key votes include director elections, auditor ratification, and equity plan share increases.HBIO
Proxy filing - Shareholders will vote on director elections, auditor ratification, executive pay, and equity plan amendments.HBIO
Proxy filing - Margins improved and 2026 guidance targets growth from new products and operational discipline.HBIO
Q4 2025
)
)
)
)
)
)
)
)